Elongation factor 2 inhib Trials

22 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Elzonris (tagraxofusp-erzs) / Menarini

2020-001543-94: Study aimed at evaluating the efficacy of Tagraxofusp, as a possible targeted therapy, in patients with Acute Myeloid Leukemia, for whom previous chemotherapy treatments have proved to be ineffective. Studio volto a valutare l'efficacia del Tagraxofusp, come possibile terapia mirata, in pazienti affetti da Leucemia Mieloide Acuta, per i quali i trattamenti chemioterapici precedenti si siano mostrati poco efficaci.

Not yet recruiting

Europe

Elzonris™ (tagraxofusp-erzs), [NA], Solution for injection

FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia CD123 + or with BPDCN immunophenotype Leucemia Mieloide Acuta CD123+ o con immunofenotipo BPDCN, AML disease that originates in the bone marrow (myeloid) and progresses rapidly (acute). Accumulation in the marrow of immature cells cause the inability to produce healthy cells and the pathology. AML malattia che origina nel midollo osseo (mieloide) e progredisce velocemente (acuta).L'accumulo nel midollo di cellule immature provoca l'incapacità di produrre cellule sane e quindi la patologia., Diseases [C] - Blood and lymphatic diseases [C15]

NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Terminated

Europe

tagraxofusp

Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia

01/24

NCT04317781: Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Terminated

Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Blastic Plasmacytoid Dendritic Cell Neoplasm

07/23

NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting

US, RoW

Tagraxofusp, Tag, Elzonris, Venetoclax, Ven, Venclexta, Azacitidine, Aza, Vidaza

Stemline Therapeutics, Inc.

Acute Myeloid Leukemia

02/28

02/30

NCI-2019-08358, NCT04216524: Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Recruiting

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine, Leurocristine, VCR, Vincrystine

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Blastic Plasmacytoid Dendritic Cell Neoplasm

12/26

TAGALONG, NCT05442216: Tagraxofusp and Azaxitadine with or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Recruiting

Tagraxofusp (Cycles 1-2), Azacitidine, Tagraxofusp (Cycles 3-12)

Joshua Zeidner, Stemline Therapeutics, Inc., University of North Carolina, Chapel Hill

Acute Myeloid Leukemia

08/27

12/27

Study 0314, NCT02268253: Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

	Jan 2021 - Mar 2021 : Data from trial for CMML and myeloﬁbrosis
	Initiation of stage 3 pivotal program of P1/2 trial for CMML
	Dec 2019 - Dec 2019: Initiation of stage 3 pivotal program of P1/2 trial for CMML
	From trial in relapsed/refractory myelofibrosis at ASH 2019
	Dec 2019 - Dec 2019: From trial in relapsed/refractory myelofibrosis at ASH 2019
	Data from P1/2 trial for CMML at ASCO 2019 [screenshot]
	Jun 2019 - Jun 2019: Data from P1/2 trial for CMML at ASCO 2019 [screenshot]
	Data from P1/2 trial for myelofibrosis at ASCO 2019 [screenshot]
	Jun 2019 - Jun 2019: Data from P1/2 trial for myelofibrosis at ASCO 2019 [screenshot]
	Updated data for CMML at ASH 2018 [screenshot]
	Dec 2018 - Dec 2018: Updated data for CMML at ASH 2018 [screenshot]
	Updated data for myelofibrosis at ASH 2018 [screenshot]
	Dec 2018 - Dec 2018: Updated data for myelofibrosis at ASH 2018 [screenshot]
	In CMML at EHA 2018 [screenshot]
	Jun 2018 - Jun 2018: In CMML at EHA 2018 [screenshot]
	In myelofibrosis at EHA 2018 [screenshot]
	Jun 2018 - Jun 2018: In myelofibrosis at EHA 2018 [screenshot]
	From MPN study including CMML and MF at ASH 2017 [screenshot]
	Dec 2017 - Dec 2017: From MPN study including CMML and MF at ASH 2017 [screenshot]
More

Completed

1/2

Canada, US

Tagraxofusp Injection, SL-401, Elzonris

Stemline Therapeutics, Inc.

Myelofibrosis, Chronic Myelomonocytic Leukemia

03/23

NCT05038592: Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Recruiting

1/2

Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS

M.D. Anderson Cancer Center

Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm

01/26

NCT06561152: Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Recruiting

1/2

Tagraxofusp, Cladribine (CLAD), Cytarabine

Stanford University, Stemline Therapeutics, Inc.

Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

10/27

10/28

NCT05032183: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated

1/2

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Leucovorin, Folinic acid, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS, Vincristine, Leurocristine, VCR, Vincrystine

M.D. Anderson Cancer Center

Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia

07/24

NCT03113643: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

	Jan 2021 - Mar 2021 : From trial for CD123 enriched AML
	Jul 2020 - Sep 2020 : Data from trial for 1L and relapsed/refractory AML or high-risk MDS

Recruiting

Azacitidine, Vidaza, SL-401, Venetoclax, Venclyxto, Venclexta

Dana-Farber Cancer Institute, Stemline Therapeutics, Inc.

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm

05/25

05/26

NCT05233618: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Recruiting

Tagraxofusp, SL-701, Elzonris

Karen Ballen, MD

Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia

07/26

10/26

NCT06498973: Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Recruiting

Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Questionnaire Administration, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL 401, SL-401, SL401, Tagraxofusp, Tagraxofusp ERZS

City of Hope Medical Center, National Cancer Institute (NCI)

Acute Myeloid Leukemia, Myelodysplastic Syndrome

04/27

NCT06414681: Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Not yet recruiting

Tagraxofusp, Pacritinib

University of Kansas Medical Center

Myelofibrosis，MF

12/26

NCT05720988: Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Withdrawn

Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS

Jonsson Comprehensive Cancer Center, Stemline Therapeutics, Inc.

Acute Myeloid Leukemia

08/25

08/26

NCT05476770: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting

US, RoW

Tagraxofusp, Elzonris, Fludarabine, Cytarabine, Cytosar, Dexamethasone, Decadron, Vincristine, Oncovin, Azacitidine, AZA, Vidaza, Methotrexate, MTX, Amethopterin, Cytarabine IT, Hydrocortisone

Therapeutic Advances in Childhood Leukemia Consortium

Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia

11/25

11/27

GO-TAG, NCT05716009: Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

Active, not recruiting

Dose Escalation -tagraxofusp-erzs, gemtuzumab ozogamicin, Dose Expansion at RP2D -tagraxofusp-erzs

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, StemlineTherapeutics, Inc.

Acute Myeloid Leukemia

12/27

12/28

D2C7 / Istari Oncology

NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting

1/2

D2C7-IT, 2141-V11

Darell Bigner, Rockefeller University

Newly Diagnosed MGMT Unmethylated Glioblastoma

02/26

02/28

NCT02303678: D2C7 for Adult Patients With Recurrent Malignant Glioma

Completed

D2C7-IT

Darell Bigner

Malignant Glioma, Brain Tumor, Recurrent

05/19

03/24

NCT04160494: D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting

D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), Tecentriq, D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)

Darell Bigner, Istari Oncology, Inc., National Cancer Institute (NCI), Genentech, Inc.

Malignant Glioma

06/24

12/27

NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting

D2C7-IT, 2141-V11, anti-CD40

Darell Bigner, Rockefeller University

Glioma, Malignant

06/26

06/27

NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting

D2C7-IT, 2141 V11

Darell Bigner, Rockefeller University

Recurrent Glioblastoma IDH Wildtype

01/29

01/30

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Elzonris (tagraxofusp-erzs) / Menarini

Not yet recruiting

Europe

Elzonris™ (tagraxofusp-erzs), [NA], Solution for injection

NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Terminated

Europe

tagraxofusp

Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia

01/24

NCT04317781: Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Terminated

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Blastic Plasmacytoid Dendritic Cell Neoplasm

07/23

NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting

US, RoW

Tagraxofusp, Tag, Elzonris, Venetoclax, Ven, Venclexta, Azacitidine, Aza, Vidaza

Stemline Therapeutics, Inc.

Acute Myeloid Leukemia

02/28

02/30

NCI-2019-08358, NCT04216524: Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Recruiting

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Blastic Plasmacytoid Dendritic Cell Neoplasm

12/26

TAGALONG, NCT05442216: Tagraxofusp and Azaxitadine with or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Recruiting

Tagraxofusp (Cycles 1-2), Azacitidine, Tagraxofusp (Cycles 3-12)

Joshua Zeidner, Stemline Therapeutics, Inc., University of North Carolina, Chapel Hill

Acute Myeloid Leukemia

08/27

12/27

Study 0314, NCT02268253: Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

	Jan 2021 - Mar 2021 : Data from trial for CMML and myeloﬁbrosis
	Initiation of stage 3 pivotal program of P1/2 trial for CMML
	Dec 2019 - Dec 2019: Initiation of stage 3 pivotal program of P1/2 trial for CMML
	From trial in relapsed/refractory myelofibrosis at ASH 2019
	Dec 2019 - Dec 2019: From trial in relapsed/refractory myelofibrosis at ASH 2019
	Data from P1/2 trial for CMML at ASCO 2019 [screenshot]
	Jun 2019 - Jun 2019: Data from P1/2 trial for CMML at ASCO 2019 [screenshot]
	Data from P1/2 trial for myelofibrosis at ASCO 2019 [screenshot]
	Jun 2019 - Jun 2019: Data from P1/2 trial for myelofibrosis at ASCO 2019 [screenshot]
	Updated data for CMML at ASH 2018 [screenshot]
	Dec 2018 - Dec 2018: Updated data for CMML at ASH 2018 [screenshot]
	Updated data for myelofibrosis at ASH 2018 [screenshot]
	Dec 2018 - Dec 2018: Updated data for myelofibrosis at ASH 2018 [screenshot]
	In CMML at EHA 2018 [screenshot]
	Jun 2018 - Jun 2018: In CMML at EHA 2018 [screenshot]
	In myelofibrosis at EHA 2018 [screenshot]
	Jun 2018 - Jun 2018: In myelofibrosis at EHA 2018 [screenshot]
	From MPN study including CMML and MF at ASH 2017 [screenshot]
	Dec 2017 - Dec 2017: From MPN study including CMML and MF at ASH 2017 [screenshot]
More

Completed

1/2

Canada, US

Tagraxofusp Injection, SL-401, Elzonris

Stemline Therapeutics, Inc.

Myelofibrosis, Chronic Myelomonocytic Leukemia

03/23

NCT05038592: Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Recruiting

1/2

M.D. Anderson Cancer Center

Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm

01/26

NCT06561152: Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Recruiting

1/2

Tagraxofusp, Cladribine (CLAD), Cytarabine

Stanford University, Stemline Therapeutics, Inc.

Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

10/27

10/28

NCT05032183: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated

1/2

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Leucovorin, Folinic acid, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS, Vincristine, Leurocristine, VCR, Vincrystine

M.D. Anderson Cancer Center

07/24

	Jan 2021 - Mar 2021 : From trial for CD123 enriched AML
	Jul 2020 - Sep 2020 : Data from trial for 1L and relapsed/refractory AML or high-risk MDS

Recruiting

Azacitidine, Vidaza, SL-401, Venetoclax, Venclyxto, Venclexta

Dana-Farber Cancer Institute, Stemline Therapeutics, Inc.

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm

05/25

05/26

NCT05233618: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Recruiting

Tagraxofusp, SL-701, Elzonris

Karen Ballen, MD

Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia

07/26

10/26

NCT06498973: Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Recruiting

City of Hope Medical Center, National Cancer Institute (NCI)

Acute Myeloid Leukemia, Myelodysplastic Syndrome

04/27

Not yet recruiting

Tagraxofusp, Pacritinib

University of Kansas Medical Center

Myelofibrosis，MF

12/26

NCT05720988: Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Withdrawn

Jonsson Comprehensive Cancer Center, Stemline Therapeutics, Inc.

Acute Myeloid Leukemia

08/25

08/26

NCT05476770: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting

US, RoW

Tagraxofusp, Elzonris, Fludarabine, Cytarabine, Cytosar, Dexamethasone, Decadron, Vincristine, Oncovin, Azacitidine, AZA, Vidaza, Methotrexate, MTX, Amethopterin, Cytarabine IT, Hydrocortisone

Therapeutic Advances in Childhood Leukemia Consortium

Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia

11/25

11/27

GO-TAG, NCT05716009: Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

Active, not recruiting

Dose Escalation -tagraxofusp-erzs, gemtuzumab ozogamicin, Dose Expansion at RP2D -tagraxofusp-erzs

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, StemlineTherapeutics, Inc.

Acute Myeloid Leukemia

12/27

12/28

D2C7 / Istari Oncology

NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting

1/2

D2C7-IT, 2141-V11

Darell Bigner, Rockefeller University

Newly Diagnosed MGMT Unmethylated Glioblastoma

02/26

02/28

NCT02303678: D2C7 for Adult Patients With Recurrent Malignant Glioma

Completed

D2C7-IT

Darell Bigner

Malignant Glioma, Brain Tumor, Recurrent

05/19

03/24

NCT04160494: D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting

D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), Tecentriq, D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)

Darell Bigner, Istari Oncology, Inc., National Cancer Institute (NCI), Genentech, Inc.

Malignant Glioma

06/24

12/27

NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting

D2C7-IT, 2141-V11, anti-CD40

Darell Bigner, Rockefeller University

Glioma, Malignant

06/26

06/27

NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting

D2C7-IT, 2141 V11

Darell Bigner, Rockefeller University

Recurrent Glioblastoma IDH Wildtype

01/29

01/30

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites